Jennison Associates’s Impax Laboratories, Inc. IPXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-18,066
| Closed | -$351K | – | 738 |
|
|
2018
Q1 | $351K | Buy |
+18,066
| New | +$355K | ﹤0.01% | 625 |
|
|
2017
Q4 | – | Sell |
-17,731
| Closed | -$360K | – | 716 |
|
|
2017
Q3 | $360K | Buy |
+17,731
| New | +$339K | ﹤0.01% | 634 |
|
|
2015
Q2 | – | Sell |
-673,653
| Closed | -$31.6M | – | 786 |
|
|
2015
Q1 | $31.6M | Sell |
673,653
-655,277
| -49% | -$26.1M | 0.03% | 396 |
|
|
2014
Q4 | $42.1M | Buy |
1,328,930
+7,650
| +0.6% | +$224K | 0.04% | 354 |
|
|
2014
Q3 | $31.3M | Sell |
1,321,280
-400,135
| -23% | -$10.3M | 0.03% | 394 |
|
|
2014
Q2 | $51.6M | Buy |
1,721,415
+309,005
| +22% | +$8.34M | 0.05% | 323 |
|
|
2014
Q1 | $37.3M | Buy |
1,412,410
+317,083
| +29% | +$7.92M | 0.04% | 371 |
|
|
2013
Q4 | $27.5M | Buy |
1,095,327
+427,839
| +64% | +$9.54M | 0.03% | 411 |
|
|
2013
Q3 | $13.7M | Sell |
667,488
-192,497
| -22% | -$3.97M | 0.01% | 461 |
|
|
2013
Q2 | $17.2M | Buy |
+859,985
| New | +$15.3M | 0.02% | 441 |
|
Jennison Associates's IPXL Position: Q2 2018 in Review
Jennison Associates sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 18,066 shares — an estimated $351K sold.
Jennison Associates first reported a position in IPXL in Q2 2013 and held it in 10 quarters. The position peaked at $51.6M in Q2 2014. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.
- Jennison Associates reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
- Jennison Associates sold 18,066 Impax Laboratories, Inc. shares in Q2 2018, an estimated $351K.
- Jennison Associates first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 10 quarters.
- Jennison Associates's Impax Laboratories, Inc. position peaked at $51.6M in Q2 2014.
- 1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.
Based on Jennison Associates's 13F filing for Q2 2018, filed 2 Aug 2018.